ESR1 and neoplasm: Although HER-2 and ER have been very informative for our understanding of patient survival, and this has lead to the eventual development of targeted agents, they do not apply to all tumor typesGiven the limited number of robust biomarkers that predict poor overall survival, the question of which should be used to guide patient care remains open [7].